Description
Semaglutide is a long-acting GLP-1 receptor agonist studied for its effects on weight management, glucose regulation, and cardiometabolic health. It is one of the most extensively researched incretin-based peptides with wide clinical use.
Benefits
- Weight management — studied for significant and sustained weight loss in clinical trials.
- Glucose regulation — linked to improved HbA1c and insulin sensitivity.
- Cardiometabolic health — interest in lowering cardiovascular risk markers.
- Appetite regulation — GLP-1 activity influences satiety and food intake.
- Widely researched — supported by large clinical programs and published data.
What researchers look at
- GLP-1 receptor activation and downstream insulin/glucagon regulation.
- SUSTAIN clinical trial program in type 2 diabetes and obesity.
- Weight loss and metabolic outcomes compared to other incretin therapies.
- Cardiovascular outcome trials showing risk reduction in high-risk populations.
Quick Specs
- Form: Lyophilized peptide
- Net per vial: 10 mg
- Purity: ≥99% (HPLC)
- Identity: MS-verified (per COA)
- Storage: 2–8 °C, protect from light
Identity Basics
- Type: GLP-1 receptor agonist
- Formula / M.W.: C187H291N45O59, ~4113.6 g/mol
- CAS: 910463-68-2
Selected Research
- PubChem entry — chemical identity:
https://pubchem.ncbi.nlm.nih.gov/compound/56843331
- SUSTAIN trials overview:
https://pubmed.ncbi.nlm.nih.gov/28916367/
- Weight management outcomes (NEJM, 2021):
https://pubmed.ncbi.nlm.nih.gov/33567185/
- Cardiovascular outcomes trial (NEJM, 2016):
https://pubmed.ncbi.nlm.nih.gov/27633186/
⚠️ Disclaimer
-
This product is intended for laboratory research use only.
-
Not for human or veterinary use.
-
Not approved for diagnostic, therapeutic, or medical applications.
-
Handle using appropriate laboratory safety procedures and personal protective equipment.
